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Background: To investigate the clinicopathological significance of androgen receptor (AR) expression in primary
breast cancers.
Patients and methods: We evaluated AR using immunohistochemistry from 413 whole sections from January 2008
to March 2009 and analyzed the relationship between AR and clinicopathological parameters. Tumors with ‡10%
nuclear-stained cells were considered to be positive for AR. The differences among variables were calculated by chi-
square test.
Results: The expression rate of AR was 72.9% higher than those of estrogen receptors (ER) and progesterone
receptors. AR expression was significant in patients with no elevated preoperative serum cancer antigen 15-3 levels,
smaller tumor size, lower histologic grade and hormone receptor-positive and non-triple-negative breast cancer.
However, AR expression was observed in 35% of triple-negative cancers. Metaplastic, medullary and mucinous types
of carcinomas showed less AR expression. In the ER-negative subgroup, AR was significantly correlated with human
epidermal growth factor receptor type 2 (HER-2) overexpression.
Conclusions: AR is expressed in a significant number of breast cancers and is associated with lower tumor burden
and favorable differentiation. There are many issues to be further investigated such as whether AR is an independent
prognostic factor, whether it is a therapeutic target for the triple-negative breast cancers and whether it is associated
with HER-2 signaling in ER-negative tumors.
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introduction
The development and progression of breast cancers are highly
dependent on the action of steroid hormones including
estradiol. Therefore, evaluation of estrogen receptor (ER) and
progesterone receptor (PgR) expression in breast cancer
patients is important in order to assess the biology of the
tumor, predict outcomes and select management strategies
such as hormonal therapy [1, 2].
In recent years, improvement in the understanding of the
molecular biology of cancer has led to the identification of new
molecular targets and the development of targeted therapies,
for example, human epidermal growth factor receptor type 2
(HER-2) and trastuzumab [3, 4]. Trastuzumab has proven
beneficial in breast cancer patients with overexpressed HER-2
in the metastatic or adjuvant setting in randomized clinical
trials [5]. Various classes of targeted anticancer agents that
block the cellular signaling pathways are still in the early phase
of clinical trials, but the USA Food and Drug Administration
has approved some agents such as lapatinib and bevacizumab.
As a result, the number of novel targeted therapies is expected
to increase [6].
Traditional histopathologic factors including tumor size,
axillary lymph node metastasis and histologic grade, as well as
new biomarkers including steroid hormone receptors and
HER-2 are valuable as predictive and prognostic factors in
breast cancer [7–9]. However, breast cancers have
heterogeneous features. It is difficult to predict outcomes in all
breast cancer patients using traditional histopathologic factors
and the same biomarkers. The validation of new emerging
biomarkers is required to determine whether they are
significantly beneficial for making a prognosis and guiding
management algorithms [1].
The androgen receptor (AR) is one such newly emerging
biomarker [10]. Many breast cancers express AR. Since AR
belongs to the nuclear steroid hormone receptor family, it
shows high structural, functional and topographic similarity to
ER and PgR [8, 11, 12]. However, AR has not been well
characterized in terms of its role as a predictive or a prognostic
factor and the clinical significance of its expression in breast
cancer patients remains unknown.
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The aim of this study was to investigate the relationship
between AR expression and clinicopathological factors in
primary breast cancer patients.
patients and methods
We reviewed the data of 652 breast cancer patients who were treated at the
Department of Surgery, Yonsei University College of Medicine in Seoul,
Korea, from January 2008 to March 2009. Among them, 457 cases (70.1%)
were consecutively evaluated for AR expression. We excluded 44 patients
who had received neoadjuvant chemotherapy and were diagnosed with
recurrent breast cancers at the time of operation. A total of 413 cases
(63.3%), including four synchronous bilateral breast cancers, were
analyzed. The mean age at diagnosis for the study cohort (n = 413) was
50.3 6 10.1 years, which was not very different from 50.0 6 10.2 years for
the patients overall (N = 652). Data regarding patient demographics and
histopathology of primary tumor were obtained by reviewing medical
records. Postmenopausal status was defined as prior bilateral
oophorectomy or serum follicle stimulating hormone levels >30 mIU/ml.
Cut-off values of the preoperative serum tumor marker carcinoembryonic
antigen (CEA) and cancer antigen 15-3 (CA 15-3) were determined to be
3.88 ng/ml and 20.11 U/ml, respectively, which are both within the 95th
percentile of healthy individuals [13]. Tumor stage was on the basis of
criteria of the Sixth American Joint Committee on Cancer. Histologic type
and grading followed the World Health Organization classification.
We evaluated AR, ER, PgR, HER-2 and Ki-67 expression in primary
breast cancer from formalin-fixed, paraffin-embedded whole sections of
surgically resected breast cancer specimens using immunohistochemistry
(IHC). Primary antibodies for AR (clone AR441; Dako, Glostrup,
Denmark), ER (clone SP1; NeoMarkers for Lab Vision, Fremont, CA), PgR
(clone PgR 636; Dako), HER-2 (polyclonal; Dako) and Ki-67 (clone MIB-1;
Dako) were used. Briefly, 4 lm-thick sections of formalin-fixed, paraffin-
embedded tissues were deparaffinized and rehydrated. After treatment with
3% hydrogen peroxide solution for 10 min to block endogenous
peroxidases, the sections were pretreated in 10 mM citrate buffer (pH 6.0)
for antigen retrieval in a microwave oven for 20 min. The aforementioned
primary antibodies were incubated, and then, the sections were processed
with EnVision Detection Systems (Dako) according to the manufacturer’s
instructions and 3, 3#-diaminobenzidine tetrahydrochloride was used as
a chromogen. The sections were counterstained with hematoxylin. These
Table 1. Relationships between AR expression and clinicopathological
factors
Factors AR positive
(%, n = 301)
AR negative
(%, n = 112)
P value
Age (years) 0.096
£35 12 (4.0) 9 (8.0)
>35 289 (96.0) 103 (92.0)
Body mass index 0.335
<25 244 (81.1) 86 (76.8)
‡25 57 (18.9) 26 (23.2)
Menopause status 0.970
Premenopausal 178 (59.1) 66 (58.9)
Postmenopausal 123 (40.9) 46 (41.1)
Preoperative CEA (ng/ml) 0.480
£3.88 285 (94.7) 104 (92.9)
>3.88 16 (5.3) 8 (7.1)
Preoperative CA 15-3 (U/ml) 0.042
£20.11 291 (96.7) 103 (92.0)
>20.11 10 (3.3) 9 (8.0)
Histologic type 0.030
Ductal 266 (88.4) 95 (84.8)
Lobular 15 (5.0) 3 (2.7)
Mucinous 5 (1.7) 7 (6.3)
Medullary 1 (0.3) 3 (2.7)
Tubular 3 (1.0) 0 (0)
Papillary 9 (3.0) 2 (1.8)
Othersa 2 (0.7) 2 (1.8)
T stage 0.035
Tis 48 (15.9) 18 (16.1)
T1 187 (62.1) 56 (50.0)
T2–3 66 (21.9) 38 (33.9)
N stage 0.626
N0 229 (76.1) 80 (71.4)
N1 56 (18.6) 27 (24.1)
N2 11 (3.7) 3 (2.7)
N3 5 (1.7) 2 (1.8)
TNM stage 0.137
Stage 0 47 (15.6) 18 (16.1)
Stage 1 148 (49.2) 42 (37.5)
Stage 2 90 (29.9) 46 (41.1)
Stage 3 16 (5.3) 6 (5.4)
Histologic grade (n = 382) <0.001
In situ carcinoma
Nonhigh grade 22 (7.9) 6 (5.8)
High grade 21 (7.5) 12 (11.7)
Invasive carcinoma
G1 74 (26.5) 13 (12.6)
G2 117 (41.9) 39 (37.9)
G3 45 (16.1) 33 (32.0)
aOther types were two apocrine and two metaplastic carcinomas. All
apocrine carcinomas expressed AR and all metaplastic carcinomas
did not.
AR, androgen receptor; CEA, carcinoembryonic antigen; CA 15-3, cancer
antigen 15-3; TNM, tumor–node–metastasis.
Table 2. Results of immunohistochemistry according to AR expression
Factor AR positive
(%, n = 301)
AR negative
(%, n = 112)
P value
ER <0.001
Negative 65 (21.6) 65 (58.0)
Positive 236 (78.4) 47 (42.0)
PgR <0.001
Negative 91 (30.2) 66 (58.9)
Positive 210 (69.8) 46 (41.1)
HER-2 0.052
Negative 235 (78.1) 97 (86.6)
Positive 66 (21.9) 15 (13.4)
Triple negativea <0.001
Non-triple negative 279 (92.7) 71 (63.4)
Triple negative 22 (7.3) 41 (36.6)
Ki-67 (n = 406) 0.806
Negative 109 (39.1) 43 (38.4)
Positive 185 (62.9) 69 (61.6)
aTriple negative represents tumors that are negative for ER, PgR and HER-2
by immunohistochemical staining.
AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor;
HER-2, human epidermal growth factor receptor type 2.
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IHC methods are routinely carried out in the Department of Pathology at
our institution.
Tumors with ‡10% nuclear-stained cells were considered positive for AR,
ER, PgR and Ki-67 expression. HER-2 immunohistochemical staining
was scored from 0 to 3+ according to the guideline indicated for
HercepTest (Dako) [14]. HER-2 IHC was considered positive when
strong (3+) membranous staining was observed, whereas cases with 0 to 2+
were regarded as negative. However, FISH test using the PathVysion HER-2
DNA Probe Kit (Abbott, IL) was carried out according to the
manufacturer’s protocols in 30 cases with equivocal (2+) staining, and three
cases with HER-2 gene-to-chromosome 17 ratio >2.2 were designated as
HER-2 overexpression. Triple-negative breast cancer was defined by lack of
expression of ER, PgR and HER-2 by IHC.
The differences between the discrete variables were evaluated by chi-
square test. Fisher’s exact test was used when appropriate. For the
comparison of the means in the case of continuous numerical data, the
independent samples’ t-test was used. A P value <0.05 was considered
statistically significant. SPSS for Windows (version 15.0; SPSS Inc.,
Chicago, IL) was used for all statistical analyses.
results
The median age at diagnosis for the study cohort was 49 years
(range 26–84 years). AR was found in 72.7% (48 of 66) of cases
of in situ carcinoma and in 72.9% (253 of 347) of invasive
carcinoma. Overall, 72.9% of breast cancers expressed AR. The
positive rates for ER, PgR, HER-2 and Ki-67 were 68.5%,
62.0%, 19.6% and 61.5%, respectively.
The relationship between AR expression and
clinicopathological factors is summarized in Table 1. AR-
negative tumors showed higher rates of elevated preoperative
serum CA 15-3 levels with statistical significance (P = 0.042).
Most types of tumor frequently express AR. However, in some
types of tumor such as metaplastic, medullary and mucinous
carcinoma, the negative rates of AR are high (P = 0.030). AR
was significantly expressed in patients with smaller tumor size
(P = 0.035) and lower histologic grade (P < 0.001). There were
no statistically significant differences between AR expression
and age at diagnosis, body mass index, menopausal status,
preoperative serum CEA levels, lymph node involvements and
tumor–node–metastasis stage.
The results of IHC for AR expression are shown in Table 2.
AR was significantly expressed in ER-positive (P < 0.001), PgR-
positive (P < 0.001) and non-triple-negative breast cancers
(P < 0.001). However, AR expression was observed in 50% (65
of 130) of ER-negative and in 35% (22 of 63) of triple-negative
cancers. There were no statistically significant differences
between AR expression and HER-2 or Ki-67 positivity.
Breast cancers represent heterogeneous features in terms of
ER status, and we evaluated the association of AR expression
with HER-2 overexpression by ER status (Table 3). In ER-
negative tumors, AR expression was significantly correlated
with HER-2 overexpression (P < 0.001). In ER-positive
tumors, however, there was no relationship between AR
expression and HER-2 overexpression (P > 0.05). In our study,
HER-2 overexpression was defined as all cases with 3+ staining
by IHC and three cases with 2+ staining by IHC and subsequent
FISH test of HER-2 gene amplification. On the basis of these
definitions, patients (n = 55) who showed 2+ staining by IHC
but did not have a subsequent FISH test were considered
non-negative for HER-2 overexpression. For strict subgroup
analysis by ER status, we excluded those patients who did not
satisfy the guidelines indicated for HercepTest [14]. In that
analysis, AR expression was also significantly correlated with
HER-2 overexpression in ER-negative tumors (P < 0.001) but
not in ER-positive tumors (P = 0.297) (Table 4).
discussion
Despite public education for cancer prevention, increased
proportions of early diagnosis and advanced management of
cancer, 200 000 women will develop breast cancer and
>40 000 women will die of breast cancer in the United States
Table 3. Comparison of AR expression with HER-2 overexpression stratified by ER status
ER-positive tumors (n = 283) ER-negative tumors (n = 130)
AR positive
(%, n = 236)
AR negative
(%, n = 47)
P value AR positive
(%, n = 65)
AR negative
(%, n = 65)
P value
HER-2 0.279 <0.001
Negative 202 (85.6) 43 (91.5) 33 (50.8) 54 (83.1)
Positive 34 (14.4) 4 (8.5) 32 (49.2) 11 (16.9)
AR, androgen receptor; ER, estrogen receptor; HER-2, human epidermal growth factor receptor type-2.
Table 4. Comparison of AR expression with HER-2 overexpression by ER status according to the guidelines for HercepTest
ER-positive tumors (n = 240) ER-negative tumors (n = 118)
AR positive
(%, n = 201)
AR negative
(%, n = 39)
P value AR positive
(%, n = 59)
AR negative
(%, n = 59)
P value
HER-2 0.297 <0.001
Negative 167 (83.1) 35 (89.7) 27 (45.8) 48 (81.4)
Positive 34 (16.9) 4 (10.3) 32 (54.2) 11 (18.6)
AR, androgen receptor; ER, estrogen receptor; HER-2, human epidermal growth factor receptor type 2.
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this year [15]. A number of known and unknown mechanisms
may play critical roles in the breast carcinogenesis, progression
and metastasis, which may be related to breast cancer
outcomes. Although some biomarkers including ER and HER-2
are well known predictive or prognostic factors in breast cancer,
it is important to identify and validate new biomarkers for
better prediction and prognostication [16, 17].
AR, one of the new biomarkers, is a member of the steroid
receptor subfamily that also includes ER. However, the role of
AR in breast cancer is still uncertain. There is some evidence
supporting a role for AR in the pathogenesis and outcome of
breast cancer. AR is expressed in >70% of breast carcinomas
and positive rates of AR are comparable with or higher than
those of ER or PgR [10, 18, 19]. In our study, AR was expressed
in 72.9% of breast cancers, which is higher than the expression
rates of both ER and PgR in breast cancer. In addition,
epidemiologic studies have reported significant associations
between increased serum androgen levels and the risk of breast
cancer [20, 21].
It has been shown that AR is frequently expressed in some
types of breast carcinoma, including apocrine or lobular
carcinoma, and less expressed in other types such as mucinous
carcinoma, although these studies were conducted on small
sample sizes [22–25]. Our study showed similar results. AR
positivity of the ductal type was 73.7%. Higher positive rates of
AR were shown in apocrine (100%), tubular (100%), lobular
(83.3%) and papillary (81.8%) types and higher negative rates
in metaplastic (0%), medullary (25%) and mucinous (41.7%)
types. These results are somewhat limited by our small sample
size.
It has been documented that AR expression is related to
positive prognostic factors, including smaller tumor size, lack
of lymph node metastasis, lower histologic grade and ER
expression and that it serves as a prognostic and predictive
factor in breast cancer [8, 9, 11, 18, 26]. Our results also show
that AR is associated with smaller size, lower histologic grade,
ER or PgR expression and non-triple-negative breast cancer.
Although the impact of AR on breast cancer outcomes has not
been clearly established, this result may provide evidence that
AR is a good prognostic marker. Since AR expression has
recently been evaluated from whole sections using IHC at our
institution, the follow-up period is still too short to assess the
impact of AR as a predictive and a prognostic factor. We are
going to evaluate the predictive and prognostic function of
AR in the near future.
It has been indicated that AR is expressed in some
proportion of triple-negative breast cancers and that it might
have a role as a prognostic marker and a therapeutic target in
this subgroup [9, 12, 19, 27]. In our study, one third of the
triple-negative cancers showed AR negativity. It is well known
that ER-negative breast cancers show aggressive biologic
features and have limited benefits to hormone therapy. In those
cases, chemotherapy or targeted therapy are the mainstays of
adjuvant treatment. New biomarkers and additional effective
treatment guidelines are necessary to predict or to improve
outcomes in these subgroups. In studies of prostate cancers,
cross talk between AR and HER-2 pathways is indicated [28].
In ER-negative tumors, functional cross talk of AR with the
HER-2 signaling pathway has been shown in in vitro and gene
expression profile studies [29, 30]. We analyzed AR expression
by ER status, and 50% of ER-negative tumors expressed AR.
AR positivity was significantly correlated with HER-2
overexpression in ER-negative tumors, but not in ER-positive
tumors, even though HER-2 overexpression is defined
according to the guidelines for HercepTest. Therefore, it is
still unknown whether AR provides a benefit as a prognostic
factor or a therapeutic molecular target and how AR and HER-
2 signaling pathway are related in these special subgroups.
In conclusion, AR is expressed in a significant number of
most types of breast cancers, except in metaplastic, medullary
and mucinous carcinoma, and is more frequently expressed
than ER and PgR. AR is also associated with lower tumor
burdens and favorable differentiation. In addition, AR is
expressed in a significant number of triple-negative breast
cancers, which indicates that AR could be a new target for the
treatment of triple-negative cancers. Many issues regarding
AR expression in breast cancer should be further assessed,
including the relationship of HER-2 signaling pathway in ER-
negative breast cancers.
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